A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age

Recruiting

Phase 2

mRNA-1083A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age

Sponsor:

Moderna

Code:

NCT06864143

Conditions

Influenza

SARS-CoV-2

Eligibility Criteria

Sex: All

Age: 18 - 64

Healthy Volunteers: Accepted

Interventions

mRNA-1083 Composition 1 Dose A Lot A

mRNA-1083 Composition 1 Dose A Lot B

mRNA-1083 Composition 1 Dose B

mRNA-1083 Composition 1 Dose C

mRNA-1083 Composition 2 Dose A

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-01. This information was provided to ClinicalTrials.gov by ModernaTX, Inc. on 2025-03-24.